Both the glutamine analog L-DON and allosteric inhibitors of glutaminase (BPTES and compound 968, respectively) have been intensively studied as cancer therapeutics.12–14 Recently, a potent and selective inhibitor of glutaminase, CB-839, has been reported. The gene discussed is GLS; the disease is cancer.